CAS No 1092939-17-7 RUXOLITINIB PHOSPHATE Pharmaceutical Intermediates
overview
Ruxolitinib phosphate is an advanced pharmaceutical compound of interest for its role in the treatment of hematological disorders.
The drug is designed to inhibit the JAK1 and JAK2 enzymes, which are critical in signaling pathways in various blood-related diseases.
By targeting these pathways, ruxolitinib phosphate helps relieve symptoms and improve quality of life in patients with myelofibrosis and other related diseases.
As a product of our integrated manufacturing and trading facilities, ruxolitinib phosphate exemplifies our commitment to quality, innovation and customer satisfaction.
Physical and chemical properties
- Solubility: Soluble in water and organic solvents, beneficial to various pharmaceutical formulations.
- STABILITY: The compound exhibits good stability under standard storage conditions, ensuring a longer shelf life and maintaining its therapeutic effects.
These properties not only enhance the performance of ruxolitinib phosphate in pharmaceutical formulations, but also enhance its versatility in various applications including the treatment of hematological disorders.
1. Targeted therapy: Ruxolitinib phosphate specifically targets the JAK1 and JAK2 enzymes, providing a targeted treatment that can enhance the therapeutic effect of myelofibrosis and polycythemia vera.
2. Symptom relief: Clinical studies have shown that ruxolitinib phosphate can significantly reduce splenomegaly and relieve systemic symptoms, improving the overall quality of life of patients.
3. Convenient dosing regimen: Ruxolitinib phosphate is typically administered orally, providing a convenient dosing schedule that improves patient compliance and overall treatment experience.
4. Safety has been confirmed: Ruxolitinib phosphate has sufficient safety and is a reliable ingredient in the treatment of blood diseases. Its use is supported by numerous research and clinical studies, ensuring it meets safety and effectiveness standards.
5. Cost Effectiveness: As a product of our integrated factory, ruxolitinib phosphate is highly competitively priced without compromising on quality. This cost-effectiveness makes it an attractive option for pharmaceutical companies and healthcare providers.
6. Sustainability: We are committed to sustainable manufacturing practices to ensure that the production of ruxolitinib phosphate has minimal environmental impact. We prioritize environmentally friendly processes and materials to meet the growing demand for sustainable pharmaceutical solutions.
In conclusion, due to its innovative mechanism of action, enhanced efficacy, and strong safety profile, ruxolitinib phosphate is the first choice for the treatment of hematological diseases.
With ruxolitinib phosphate, you can be confident that you are choosing a reliable and effective solution for your pharmaceutical needs.
As a factory integrating production and trading, we are committed to providing customers with high-quality products that meet the highest industry standards.
Partner with us today to experience the benefits of ruxolitinib phosphate and enhance your drug offering to treat blood disorders.